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Abstract
Background: Although the nodal ratio (NR) has been recognized as a prognostic factor in breast cancer, its clinical
implication in patients with 1-3 positive nodes (N1) remains unclear. Here, we evaluated the prognostic value of
the NR and identified other clinico-pathologic variables associated with poor prognosis in these patients.
Methods: We analyzed 130 patients with N1 invasive breast cancer who were treated at Seoul National University
Bundang Hospital from March 2003 to December 2007. Disease-free survival (DFS), locoregional recurrence-free
survival (LRRFS), and distant metastasis-free survival (DMFS) were compared according to the NR with a cut-off
value of 0.15.
Results: We followed patients’ recovery for a median duration of 59 months. An NR > 0.15 was found in 23.1% of
patients, and a median of 18 nodes were dissected per patient (range 1-59). The NR was statistically independent
from other prognostic variables, such as patient age, T stage, extent of surgery, pathologic factors in the chi square
test. On univariate analysis, patients with a NR > 0.15 had significantly lower 5-year LRRFS (88.7% vs. 97.9%, p =
0.033) and 5-year DMFS (81.3% vs. 96.4%, p = 0.029) and marginally lower 5-year DFS (81.3% vs. 94.0%, p = 0.069)
than those with a NR ≤0.15, respectively. Since the predictive power of the NR was found to differ with diverse
clinical and pathologic variables, we performed adjusted analysis stratified by age, pathologic characteristics, and
adjuvant treatments. Only young patients with a NR > 0.15 showed significantly lower DFS (p = 0.027) as well as
those presenting an unfavorable pathologic profile such as advanced T stage (p = 0.034), histologic grade 3 (p =
0.034), positive lymphovascular invasion (p = 0.037), involved resection margin (p = 0.007), and no chemotherapy
(p = 0.014) or regional radiotherapy treatment (p = 0.039). On multivariate analysis, a NR > 0.15 was significantly
associated with lower DFS (p = 0.043) and DMFS (p = 0.012), but not LRRFS (p = 0.064).
Conclusions: A NR > 0.15 was associated with an increased risk of recurrence, especially in young patients with
unfavorable pathologic profiles.
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Background
The presence of axillary lymph node metastasis is one of
the most important factors affecting prognosis in patients
with breast cancer [1]. According to the current 7th edi-
tion of the American Joint Committee on Cancer staging
system, N stage in breast cancer is solely determined by
the number of positive nodes [2]. In patients with inappro-
priately dissected axillary nodes, however, a discrepancy
may exist between the absolute number of positive nodes
and the substantive extent of axillary node metastasis [3].
Therefore, the nodal ratio (NR), defined as the absolute
number of involved nodes/number of excised nodes, has
been suggested to address this discrepancy [4]. Recent stu-
dies have shown the prognostic value of the NR and even
proposed the possibility of NR as an alternative or a com-
plement to N staging in node-positive breast cancer
[5-13]. However, no consensus has been reached for the
appropriate criteria to discriminate between low- and
high-risk groups of NR for breast cancer with 1-3 positive
nodes.
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value of the NR and identified other clinico-pathologic
variables associated with poor prognosis in N1 breast
cancer patients.
Methods
Patients
We retrospectively analyzed 130 patients with N1 inva-
sive breast cancer who were treated at Seoul National
University Bundang Hospital (SNUBH) from March
2003 to December 2007. Patients who had received
neoadjuvant chemotherapy prior to surgery were
excluded. We collected not only treatment modality
information such as type of surgery, type of systemic
treatment, and radiation field, but also detailed clinico-
pathologic prognostic factors such as age, pathologic
stage, histologic type and grade, number of excised and
positive nodes, estrogen/progesterone receptor (ER/PR)
status, human epithelial growth factor receptor family 2
(HER2) status, presence of extracapsular extension
(ECE), presence of lymphovascular invasion (LVI), and
resection margin status. A close margin was defined as
t h ep r e s e n c eo fi n v a s i v ec a r c i n o m aw i t h i n2m mo ft h e
surgical margin of resection.
Patient grouping according to the nodal ratio
We categorized the patients into two NR groups: low NR
(LNR; ≤0.15) and high NR (HNR; > 0.15). Disease-free sur-
vival (DFS), locoregional recurrence-free survival (LRRFS),
and distant metastasis-free survival (DMFS) were com-
pared between groups. We defined locoregional recur-
r e n c ea st h ef i r s ts i t eo fr e c u r r e n c ei n v o l v i n gr e s i d u a l
breast or chest wall (local) tissue and/or axillary, supra- or
infraclavicular, and internal mammary nodes (regional).
For cases in which locoregional recurrence and distant
metastasis simultaneously occurred, we counted both fail-
ure patterns.
Statistical analysis
To make comparisons between the two groups, we used
the chi-square test or Fisher’s exact test for categorical
data and independent sample t-test for continuous data.
The Kaplan-Meier method was used for DFS, LRRFS, and
DMFS probability, and survival according to different vari-
ables was compared by the log-rank test. The Cox propor-
tional hazard method was used to perform multivariate
analysis for predictors of survival. We included variables
that showed significance in the univariate analysis or were
otherwise were considered to be confounders in the multi-
variate analysis. All statistical analyses were performed
with Statistical Package for the Social Sciences (version
17.0; SPSS, Chicago, IL). We considered p values equal to
or less than 0.05 to be statistically significant.
Results
Patient and tumor characteristics
Of the 130 patients, the LNR group included 100 patients
and the HNR group included 30 patients. Patient charac-
teristics for these two groups are summarized in Table 1.
The median number of excised nodes per patient was 18
(range, 1-59) for both groups combined, and was signifi-
cantly higher in the LNR group than in the HNR group
(20 vs. 7, p < 0.001). RT was used to treat 46 (46%) LNR
patients and 20 (66.7%) HNR patients; among these,
regional RT was more frequently used in the HNR group
(50.0% vs. 10.9%, p = 0.001). The local RT field consisted
of the whole breast or chest wall only. In contrast, supra-
clavicular lymph nodes and/or internal mammary lymph
nodes were included in the locoregional RT field. Che-
motherapy was used to treat 92 (92%) LNR patients and
25 (83.3%) HNR patients. Taxane-containing regimens
such as AC (adriamycin and cyclophosphamide) were
most frequently prescribed. The tumor characteristics in
the two groups are summarized in Table 2. Infiltrating
ductal carcinoma was the most frequent tumor histology
in both groups, but was more dominant in the LNR
group (92.0% vs. 73.3%, p = 0.011). The NR was a statisti-
cally independent variable from other prognostic vari-
ables including patient age, extent of surgery, and
pathologic factors such as ECE, LVI, tumor grade, margin
status, ER/PR, and HER2 status.
Follow-up and patterns of failure
We followed patients’ recovery for a median duration of
59 months (range, 10-89 months) for both groups
although the LNR group had a longer duration of fol-
low-up (p = 0.013). Both groups showed distant metas-
tasis as the dominant failure pattern in eight of nine
patients who experienced any failures. These details are
summarized in Table 3.
Univariate analysis of different prognostic factors
The univariate analysis results for prognostic factors are
summarized in Table 4. According to the univariate
analysis, patients with a NR > 0.15 had significantly
lower 5-year LRRFS (88.7% vs. 97.9%, p = 0.033) and 5-
year DMFS (81.3% vs. 96.4%, p = 0.029) and marginally
lower 5-year DFS (81.3% vs. 94.0%, p = 0.069) than
those with a NR ≤0.15 (Figure 1).
The effect of NR on DFS stratified by other prognostic
factors
Since the prognostic power of the NR was found to dif-
fer according to diverse clinical and pathologic variables,
we performed adjusted analysis stratified by age, patho-
logic characteristics, and adjuvant treatments. The HNR
group showed significantly lower 5-year DFS exclusively
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profile: young age (p = 0.027), advanced T stage (p =
0.034), high grade (p = 0.034), the presence of LVI (p =
0.037), involved resection margin (p = 0.007) and the
lack of chemotherapy (p = 0.014) or regional RT (p =
0.039; Table 5). The DFS curves according to NR with
and without regional RT are presented in Figure 2.
Multivariate analysis of different prognostic factors
According to the multivariate analysis, a NR > 0.15 was
significantly associated wi t hl o w e rD F S( p=0 . 0 4 3 )a n d
D M F S( p=0 . 0 1 2 )b u tn o tL R R F S( p=0 . 0 6 4 ;T a b l e6 ) .
Patients not treated with chemotherapy showed a ten-
dency of increased distant metastasis.
Discussion
The prognostic value of NR is supported by several stu-
dies [4-13]. Vinh-Hung et al. reported the superiority of
NR over pN stage in predicting disease-specific survival,
and Danko et al. revealed that the prognostic value of
NR for disease-free survival remained significant even
when stratified by pN stage [8,10]. Recently, Ahn et al.
showed that NR is a better predictor of disease-free sur-
vival than pN stage, especially in patients with high-risk
features such as young age, HER2-enriched or triple-
negative tumor, and recommended that NR should be
preferentially considered in decision making for adjuvant
treatment [13].
Although most studies used a value between 0.20 and
0.25 as a minimal cut-off threshold to distinguish risk
groups, there is no consensus on which value is the
m o s tr e l i a b l e[ 5 - 1 4 ] .W eu s e d0 . 1 5a sac u t - o f fv a l u e ,
which may be considered somewhat low. Because the
number of positive nodes is inevitably limited in the N1
category, however, the distribution of the NR is strongly
affected by the number of nodes sampled. While other
studies have focused on patients with between 10 and
16 excised nodes, the present study investigated patients
with a median of 18 excised nodes.
Extensive data suggest that other clinico-pathologic
findings also can predict an increased risk of locoregio-
nal recurrence and even distant metastasis, such as
young age, higher histologic grade, negative hormone
receptors, presence of ECE, presence of LVI, and
Table 1 Patient characteristics
No. of patients (%)
NR < 0.15
(n = 100)
NR > 0.15
(n = 30)
p value Total
(n = 130)
Age (years) 0.225
median (range) 46 (25-79) 50 (32-82) 47 (25-82)
Excised LN (No.) < 0.001
median (range) 20 (7-59) 7 (1-18) 18 (1-59)
Breast resection 0.290
BCS 49 (49.0) 18 (60.0) 67 (51.5)
MRM 51 (51.0) 12 (40.0) 63 (48.5)
LN resection 0.071
SLNB only 3 (3.0) 4 (13.3) 7 (5.4)
SLNB + ALND 68 (68.0) 20 (66.7) 88 (67.7)
ALND 29 (29.0) 6 (20.0) 35 (26.9)
Radiotherapy 0.047
no 54 (54.0) 10 (33.3) 64 (49.2)
yes 46 (46.0) 20 (66.7) 66 (50.8)
Extent of radiotherapy 0.001
local 41 (89.1) 10 (50.0) 51 (77.2)
locoregional 5 (10.9) 10 (50.0) 15 (22.8)
Chemotherapy 0.176
no 8 (8.0) 5 (16.7) 13 (10.0)
yes 92 (92.0) 25 (83.3) 117 (90.0)
Regimen 0.141
CMF 12 (13.0) 7 (28.0) 19 (16.2)
FEC/FAC 31 (33.7) 9 (36.0) 40 (34.2)
ACT 49 (53.3) 9 (36.0) 58 (49.6)
Abbreviations: LN, lymph node; BCS, breast-conserving surgery; MRM, modified radical mastectomy; SLNBx, sentinel lymph node biopsy; ALND, axillary lymph
node dissection; CMF, cyclophosphamide/methotrexate/5-fluorouracil; FEC, 5-FU/epirubicin/cyclophosphamide; FAC, 5-FU/adriamycin/cyclophosphamide; ACT,
adriamycin/cyclophosphamide/paclitaxel
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No. of patients (%)
NR ≤0.15
(n = 100)
NR > 0.15
(n = 30)
p value Total
(n = 130)
Histology 0.011
IDC 92 (92.0) 22 (73.3) 114 (87.7)
others 8 (8.0) 8 (26.7) 16 (12.3)
T stage 0.166
T1a/T1b 8 (8.0) 6 (20.0) 14 (10.8)
T1c 42 (42.0) 12 (40.0) 54 (41.5)
T2 49 (49.0) 10 (33.3) 59 (45.4)
T3 1 (1.0) 2 (6.7) 3 (2.3)
ER 0.459
(-) 23 (23.0) 5 (16.7) 28 (21.5)
(+) 77 (77.0) 25 (83.3) 102 (78.5)
PR 0.155
(-) 41 (41.0) 8 (26.7) 49 (37.7)
(+) 59 (59.0) 22 (73.3) 81 (62.3)
HER2 0.866
(-) 72 (72.0) 25 (83.3) 107 (82.3)
(+) 18 (18.0) 5 (16.7) 23 (17.7)
unknown 10 (10.0) 0 (0.0)
ECE 0.183
(-) 74 (74.0) 22 (73.4) 97 (74.6)
(+) 26 (26.0) 7 (23.3) 33 (25.4)
unknown 0 (0.0) 1 (3.3)
LVI 0.175
(-) 52 (52.0) 14 (47.7) 67 (51.5)
(+) 48 (48.0) 15 (50.0) 63 (48.5)
unknown 0 (0.0) 1 (3.3)
Resection margin 0.868
(-) 91 (91.0) 27 (90.0) 118 (90.8)
close or (+) 9 (9.0) 3 (10.0) 12 (9.2)
Tumor grade 0.297
G1/G2 63 (63.0) 22 (73.3) 85 (65.4)
G3 37 (37.0) 8 (26.7) 45 (34.6)
Abbreviations: NR, nodal ratio; IDC, infiltrating ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; ECE, extracapsular extension; LVI,
lymphovascular invasion; RM, resection margin
Table 3 Clinical status and patterns of failure
No. of patients (%)
NR ≤0.15
(n = 100)
NR> 0.15
(n = 30)
Total
(n = 130)
Follow-up (months)
median (range) 61 (10-89) 48 (26-78) 59 (10-89)
Clinical Status
NED 96 (96.0) 26 (86.6) 122 (93.9)
alive with disease 4 (4.0) 2 (6.7) 6 (4.6)
cause-specific death 0 (0.0) 2 (6.7) 2 (1.5)
intercurrent death 0 (0.0) 0 (0.0) 0 (0.0)
Patterns of failure
LRR only 1 (20.0) 0 (0.0) 1 (11.0)
DM only 3 (60.0) 1 (25.0) 4 (44.5)
LRR+DM 1 (20.0) 3 (75.0) 4 (44.5)
Abbreviations: NR, nodal ratio; NED, no evidence of disease; LRR, locoregional recurrence; DM, distant metastasis
Han et al. Radiation Oncology 2011, 6:131
http://www.ro-journal.com/content/6/1/131
Page 4 of 10Table 4 Univariate analysis for 5-year LRRFS, DMFS, and DFS
Variable No. of pts 5-year LRRFS
(%)
5-year DMFS
(%)
5-year DFS
(%)
Age
≤40 31 92.7 84.3 84.3
> 40 99 96.8 96.2 93.7
p = 0.348 p = 0.078 p = 0.138
T stage
T1 68 96.5 96.7 94.6
T2/3 62 95.0 89.5 87.7
p = 0.578 p = 0.108 p = 0.229
Nodal ratio
≤0.15 100 97.9 96.4 94.0
> 0.15 30 88.7 81.3 81.3
p = 0.033 p = 0.029 p = 0.069
ER
(-) 28 96.4 96.4 95.4
(+) 102 95.6 92.3 89.8
p = 0.895 p = 0.462 p = 0.374
PR
(-) 49 98.0 98.0 98.0
(+) 81 94.5 90.5 87.5
p = 0.403 p = 0.111 p = 0.087
HER2
(-) or unknown 107 94.4 92.0 89.7
(+) 23 100.0 100.0 100.0
p = 0.421 p = 0.180 p = 0.163
Histologic grade
G1/G2 85 97.3 94.3 92.7
G3 45 93.1 91.7 89.2
p = 0.203 p = 0.354 p = 0.510
ECE
(-) or unknown 97 95.5 91.3 90.2
(+) 33 96.8 100.0 95.2
p = 0.639 p = 0.117 p = 0.332
LVI
(-) or unknown 67 96.4 95.0 93.3
(+) 63 95.1 91.6 89.7
p = 0.639 p = 0.927 p = 0.768
RM
(-) 118 96.2 94.9 92.7
close or (+) 12 91.7 83.3 83.3
p = 0.431 p = 0.213 p = 0.268
Surgery
BCS 67 98.5 95.5 95.5
MRM 63 93.1 91.9 88.1
p = 0.160 p = 0.556 p = 0.345
Regional RT
no 115 96.2 93.3 91.2
yes 15 93.3 93.3 93.3
p = 0.503 p = 0.976 p = 0.935
Chemotherapy
no 13 92.3 79.1 79.1
yes 117 96.3 94.9 92.8
p = 0.401 p = 0.104 p = 0.173
Abbreviations: LRRFS, locoregional recurrence-free survival; DMFS, distant metastasis-free survival; DFS, disease-free survival; ER, estrogen receptor; PR, progesterone
receptor; ECE, extracapsular extension; LVI, lymphovascular invasion; RM, resection margin; BCS, breast-conserving surgery; MRM, modified radical mastectomy
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Page 5 of 10inadequate resection margins [15-19]. Recently, Truong
et al. reported that T1-T2 breast cancer patients with
one to three positive nodes, young age (< 50 years), his-
tologic grade 3, or ER-negative disease had high 10-year
locoregional recurrence risks (up to 20%), even after
breast-conserving surgery was followed by whole breast
radiotherapy [15]. In the current study, those findings
were not significant factors for locoregional recurrence
or distant metastasis independently but showed selective
significance in adjusted analysis combined with the NR.
Regardless of the extent of surgery, substantially high
locoregional recurrence rates have been reported in
patients with 1-3 positive nodes [15,20-24]. Locoregional
recurrence also has been linked to distant metastasis
and long-term breast cancer mortality [25-28]. In a
meta-analysis of five National Surgical Adjuvant Breast
and Bowel Project (NSABP) trials, patients who experi-
enced locoregional recurrence had a considerably lower
5-year DMFS: 51.4% after ipsilateral breast tumor recur-
rence, 31.5% after axillary recurrence, and 12.1% after
supraclavicular metastasis, respectively [27]. Data from
the Breast Cancer Trialists’ Collaborative Group
(BCTCG) showed the overall absolute reduction of 5-
year locoregional recurrence by 19%, resulting in a 5%
Figure 1 LRRFS, DMFS, and DFS according to NR. (a) LRRFS
according to NR. (b) DMFS according to NR. (c) DFS according to
NR. Abbreviations: LRRFS, locoregional recurrence-free survival;
DMFS, distant metastasis-free survival; DFS, disease-free survival; NR,
nodal ratio.
Table 5 Adjusted analysis for DFS
5-year DFS (%)
No. of pts NR ≤0.15 NR > 0.15 p value
Age
≤40 31 90.4 53.3 0.027
> 40 99 95.4 87.3 0.361
T stage
T1 68 95.4 90.9 0.586
T2/3 62 92.3 66.7 0.034
Histologic grade
G1/2 85 94.7 84.7 0.387
G3 45 92.6 75.0 0.034
LVI
(-) or unknown 67 94.0 87.5 0.849
(+) 63 93.8 75.8 0.037
RM
(-) 118 93.2 90.9 0.594
close or (+) 12 100.0 33.3 0.007
Regional RT
no 115 93.7 69.7 0.039
yes 15 100.0 90.0 0.480
Chemotherapy
no 13 100.0 80.0 0.014
yes 117 93.4 90.7 0.556
Abbreviations: DFS, disease-free survival; NR, nodal ratio; ECE, extracapsular
extension; LVI, lymphovascular invasion; RM, resection margin
Han et al. Radiation Oncology 2011, 6:131
http://www.ro-journal.com/content/6/1/131
Page 6 of 10overall absolute reduction of 15-year breast cancer mor-
tality risk in patients who underwent either breast-con-
serving surgery or mastectomy [28]. In the current
study, the HNR group showed lower LRRFS, DMFS, and
DFS. However, it is inconclusive whether decreased risk
of distant metastasis resulted from decreased locoregio-
nal recurrence because only a small number of patients
experienced locoregional recurrence.
The National Cancer Institute of Canada Clinical Trials
Group (NCIC-CTG) has suggested that adding regional
RT may improve survival compared with whole breast
RT only when administered after breast-conserving
surgery in patients who have T1-T2 breast cancer with
N1 or moderate to high risk N0 [29]. The current study
revealed that regional RT reduced the risk of distant
metastasis in the HNR group only; however, this finding
could also support the interpretation that regional RT is
unnecessary for LNR patients who have undergone ade-
quate axillary dissection and had no poor prognostic fac-
tors. For optimization of the locoregional modality, it is
necessary to better define the selection criteria for adju-
v a n tR T .T h eN Rm a yb eau s e f u li n d i c a t o rf o rd e c i d i n g
whether to use adjuvant regional RT to treat patients
with N1 disease.
Figure 2 Adjusted analysis for DFS with or without regional RT. (a) DFS according to nodal ratio with regional RT. (b) DFS according to
nodal ratio without regional RT. Abbreviations: DFS, disease-free survival; NR, nodal ratio.
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grade 3, estrogen receptor-negative breast carcinomas,
or presence of LVI are all considered to be related to
the risk of regional recurrence. Previous studies have
shown that sampling fewer than 10 axillary nodes is
associated with an increased risk of subsequent locore-
gional recurrence [15,23,24,30]. Tai et al. included in
their study only patients with 10 or more excised nodes
in order to avoid the possibility of an increased regional
relapse rate resulting from understaging or undertreat-
ment [6]. The adjuvant regional RT could compensate
for the compromised regional control resulting from
inadequate axillary dissection; however, this result does
not directly apply to patients in the HNR group who
have undergone adequate axillary dissection and remain
at substantial risk for locoregional recurrence [31].
Conclusions
T h er e s u l t so ft h i ss t u d ya s s o c i a t eaN R>0 . 1 5w i t h
increased risk of disease recurrence, especially in young
patients with unfavorable pathologic profiles.
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